Immunologically active phenotype is associated with response to PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer. Immunologically active phenotype is associated with response to PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer

Immunotherapy in immunologically active tumors may improve prognosis of non-small cell lung carcinomas (NSCLC). Our objective was to develop a reliable and stable scoring system for the identification of immunologically active HNSCC and to evaluate its association with response to immunotherapies. A Hot Oral Tumor (HOT) score was developed using data from The Cancer Genome Atlas in human-papillomavirus negative head and neck squamous cell carcinomas; it was computed in 92 patients with early stage NSCLC treated with surgery to evaluate the prognostic impact of the HOT score. Overall design: In 92 patients with surgically treated NSCLC, gene expression profiles were generated using formalin-fixed paraffin embedded biopsies or surgically resected specimens collected prior to treatment initiation. Gene expression profiles were generated using HTG EdgeSeq technology and the Oncology Biomarker Panel (OBP). >>>Submitter states that raw data are currently unavailable. They are working with the sequencing company to retrieve the raw files<<<